Gilead Sciences Inc diskutieren
Gilead Sciences Inc
WKN: 885823 / Symbol: GILD / Name: Gilead Sciences / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
102,98 €
0,39 %
Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at HSBC Holdings plc. They set a "reduce" rating and a $71.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $91.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $95.00 price target on the stock, up previously from $88.00.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $115.00 to $105.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Mizuho from $101.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $105.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at TD Cowen from $90.00 to $85.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Maxim Group from $90.00 to $85.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Raymond James from a "market perform" rating to an "outperform" rating. They now have a $93.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $95.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $100.00 price target on the stock, up previously from $78.00.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at JPMorgan Chase & Co. from $95.00 to $100.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Sanford C. Bernstein. They set an "outperform" rating and a $105.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at BMO Capital Markets from $85.00 to $94.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $96.00 price target on the stock, up previously from $74.00.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Piper Sandler from $95.00 to $105.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Wells Fargo & Company from $100.00 to $105.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Neueste Beiträge
Guggenheim in Accenture plc A diskutieren